Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy

Keyphrases

• Allopurinol 100%
• Diabetic Cardiomyopathy 100%
• Xanthine Oxidase Inhibitor 100%
• Diabetes 80%
• Fibrosis 80%
• Poly(ADP-ribose) Polymerase 80%
• Inducible Nitric Oxide Synthase 60%
• Tyrosine 60%
• Xanthine Oxidase 60%
• Apoptosis 40%
• Liver 40%
• Fibronectin 40%
• Cardiac Dysfunction 40%
• Chromatin 40%
• Nitrosative Stress 40%
• Endothelial Nitric Oxide Synthase (eNOS) 40%
• Caspase-3 40%
• Diabetic Animals 40%
• P40phox 40%
• P22phox 40%
• P47phox 40%
• Immunohistochemistry 20%
• Molecular Biology Techniques 20%
• MRNA Expression 20%
• Placebo 20%
• Vascular Dysfunction 20%
• Collagen 20%
• Type 1 Diabetes Mellitus (T1DM) 20%
• Protein Level 20%
• Streptozotocin 20%
• Biochemical Methods 20%
• Myocardial Contraction 20%
• Left Ventricular Function 20%
• Fibrosis Marker 20%
• Type I Diabetes 20%
• ROS Generation 20%
• Gp91phox 20%
• Myocardial Performance 20%
• Load-dependent 20%
• Enhanced Accumulation 20%
• Left Ventricular Systolic Function 20%
• Molecular Biochemistry 20%
• Volume System 20%
• Load-independent 20%
• Pressure-volume 20%
• Collagen Type 1 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Fibrosis 100%
• Allopurinol 100%
• Diabetic Cardiomyopathy 100%
• Xanthine Oxidase Inhibitor 100%
• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase 80%
• Xanthine Oxidase 80%
• 3 Nitrotyrosine 60%
• Fibronectin 40%
• Diabetes Mellitus 40%
• C57BL 6 Mouse 40%
• Connective Tissue Growth Factor 40%
• Messenger RNA 40%
• Placebo 20%
• Streptozotocin 20%
• Insulin Dependent Diabetes Mellitus 20%
• Caspase 3 20%
• Collagen Type 1 20%